PE20030973A1 - Cuerpos de inclusion que transportan glicerol-fosfato aceptables para uso farmaceutico - Google Patents
Cuerpos de inclusion que transportan glicerol-fosfato aceptables para uso farmaceuticoInfo
- Publication number
- PE20030973A1 PE20030973A1 PE2003000064A PE2003000064A PE20030973A1 PE 20030973 A1 PE20030973 A1 PE 20030973A1 PE 2003000064 A PE2003000064 A PE 2003000064A PE 2003000064 A PE2003000064 A PE 2003000064A PE 20030973 A1 PE20030973 A1 PE 20030973A1
- Authority
- PE
- Peru
- Prior art keywords
- inclusion bodies
- composition
- refers
- pharmaceutical use
- inflammatory
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G19/00—Compounds of tin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G15/00—Compounds of gallium, indium or thallium
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/24—Electrically-conducting paints
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Nanotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
Abstract
SE REFIERE A UNA COMPOSICION CAPAZ DE PRODUCIR UNA RESPUESTA ANTIINFLAMATORIA IN VIVO CARACTERIZADA PORQUE COMPRENDE LIPOSOMAS COMO CUERPOS DE INCLUSION ACEPTABLES PARA USO FARMACEUTICO DE UNA TAMANO DE 20 nm AY 500 µm QUE COMPRENDE UNA PLURALIDAD DE GRUPOS GLICEROL-FOSFATO O GRUPOS QUE SE PUEDEN CONVERTIR EN GLICEROLFOSFATO. LA COMPOSICION ESTA LIBRE DE ENTIDADES NO LIPIDICAS Y LA COMPOSICION COMPRENDE ENTRE 60 Y 100% DE FOSFATIDILGLICEROL (PG) Y EL RESTO DEL LIPOSOMA COMPRENDE FOSFATIDILCOLINA. SE REFIERE TAMBIEN A UN METODO DE TRATAMIENTO DE UN TRASTORNO MEDIADO POR EL FUNCIONAMEIENTO DE CELULAS T QUE COMPRENDE LA ADMINISTRACION DE UNA CANTIDAD EFICAZ DE CUERPOS DE INCLUSION QUE TRANSPORTAN GRUPOS GLICEROL FOSFATO PARA INHIBIR Y/O REDUCIR EL AVANCE DE DICHO TRASTORNO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS, INMUNOLOGICOS MEDIADO POR CELULAS T, NEURODEGENERATIVOS, NEUROINFLAMATORIOS
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002368656A CA2368656A1 (en) | 2002-01-21 | 2002-01-21 | Receptor-ligand pairing for anti-inflammatory response |
US5138102A | 2002-01-22 | 2002-01-22 | |
US35142702P | 2002-01-28 | 2002-01-28 | |
US36462002P | 2002-03-18 | 2002-03-18 | |
US37210602P | 2002-04-15 | 2002-04-15 | |
US40085702P | 2002-08-02 | 2002-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030973A1 true PE20030973A1 (es) | 2003-12-09 |
Family
ID=27617925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000064A PE20030973A1 (es) | 2002-01-21 | 2003-01-21 | Cuerpos de inclusion que transportan glicerol-fosfato aceptables para uso farmaceutico |
Country Status (14)
Country | Link |
---|---|
US (3) | US20030175334A1 (es) |
EP (2) | EP1467740A1 (es) |
JP (2) | JP2005515242A (es) |
KR (1) | KR20040089118A (es) |
CN (1) | CN1620301A (es) |
AR (2) | AR047005A1 (es) |
BR (2) | BR0307041A (es) |
CA (5) | CA2368656A1 (es) |
EA (1) | EA007426B1 (es) |
MA (1) | MA27168A1 (es) |
MX (1) | MXPA04007042A (es) |
PE (1) | PE20030973A1 (es) |
TW (2) | TW200302281A (es) |
WO (3) | WO2003061667A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050058698A1 (en) * | 2002-01-21 | 2005-03-17 | Nolan Yvonne Mairead | Pharmaceutically acceptable phosphate-glycerol carrying bodies and uses relating to Parkinson's Disease |
WO2004082688A1 (en) * | 2003-03-20 | 2004-09-30 | Vasogen Ireland Limited | Phosphatidylglycerol (pg) receptor agonists and antagonists |
CN1826123A (zh) * | 2003-07-21 | 2006-08-30 | 瓦索金爱尔兰有限公司 | 急性炎症状态的治疗方法 |
US20060008517A1 (en) * | 2004-07-09 | 2006-01-12 | Lynch Marina A | Treatment of age-related memory impairment |
AR052642A1 (es) * | 2004-09-15 | 2007-03-28 | Vasogen Ireland Ltd | Tratamiento de esclerosis multiple con liposomas que contienen fosfatidilglicerol |
WO2006107107A1 (ja) * | 2005-04-01 | 2006-10-12 | Fumitaka Ohsuzu | リン脂質小胞体を含む心筋保護剤および虚血・再潅流時の心筋障害を予防する方法 |
WO2007038549A1 (en) * | 2005-09-26 | 2007-04-05 | Vasogen Ireland Limited | Treatment of inflammation and vascular abnormalities of the eye |
JP5815915B2 (ja) * | 2005-10-11 | 2015-11-17 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 過活動膀胱障害の治療のためのスフィンゴミエリンリポソーム |
WO2007131329A1 (en) * | 2006-05-12 | 2007-11-22 | Vasogen Ireland Limited | Treatment of ubiquitin-proteasome system dysfunction related disorders |
NZ598906A (en) * | 2009-08-21 | 2014-08-29 | Targeted Delivery Technologies Ltd | Vesicular formulations |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
CN109549925B (zh) * | 2012-06-14 | 2022-06-17 | 伯尔尼大学 | 用于治疗细菌感染的定制脂质体 |
JP6417648B2 (ja) * | 2013-07-30 | 2018-11-07 | 株式会社豊田中央研究所 | エタノールアミンリン酸の利用 |
JP6139781B2 (ja) * | 2014-04-04 | 2017-05-31 | 国立大学法人大阪大学 | リゾリン脂質受容体を活性化する物質を含有する薬剤送達促進剤 |
JP6103143B1 (ja) * | 2015-05-18 | 2017-03-29 | 不二製油株式会社 | IL−1β産生抑制作用を有する食品添加用組成物 |
EP3954361A1 (en) | 2015-06-30 | 2022-02-16 | Sequessome Technology Holdings Limited | Multiphasic compositions |
WO2018158375A1 (en) * | 2017-03-02 | 2018-09-07 | Combioxin Sa | Liposomes for inhibiting biofilm formation |
CN115531399A (zh) * | 2022-09-15 | 2022-12-30 | 首都医科大学 | 溶血磷脂酰胆碱在治疗阿尔茨海默病中的应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2518718A1 (fr) * | 1981-12-23 | 1983-06-24 | Djelalian Madeleine | Procede pour capter et exploiter au maximum le rayonnement solaire global, dispositifs pour la mise en oeuvre de ce procede et capteurs solaires en resultant |
US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4789633A (en) * | 1984-04-19 | 1988-12-06 | University Of Tennessee Research Corporation | Fused liposome and acid induced method for liposome fusion |
US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
US4812314A (en) * | 1986-02-24 | 1989-03-14 | Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization | Lipid replacement therapy |
US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
US5229376A (en) * | 1986-09-25 | 1993-07-20 | The United States Of America As Represented By The Secretary Of The Army | Encapsulated plant-derived phosphatidylinositol (PI) compositions for the prevention of mitogenically induced cell proliferation |
US4963297A (en) * | 1987-12-22 | 1990-10-16 | The Liposome Company, Inc. | Spontaneous vesticulation of multilamellar liposomes |
US4863739A (en) * | 1987-05-19 | 1989-09-05 | Board Of Regents, The University Of Texas System | Liposome compositions of anthracycline derivatives |
FR2617170B1 (fr) * | 1987-06-25 | 1989-12-22 | Inst Nat Sante Rech Med | Nouveaux derives peptidiques et leur application notamment en therapeutique |
IL93996A0 (en) * | 1989-04-04 | 1991-01-31 | Alcon Lab Inc | Pharmaceutical composition containing a liposome |
AU639925B2 (en) * | 1989-04-18 | 1993-08-12 | Nexstar Pharmaceuticals, Inc. | Liposomal targeting of ischemic tissue |
FR2658418B1 (fr) * | 1990-02-20 | 1994-09-02 | Synthelabo | Compositions pharmaceutiques a base de phospholipides. |
US5188951A (en) * | 1990-04-17 | 1993-02-23 | The Liposome Company, Inc. | Enzymatic synthesis of soluble phosphatides from phospholipids |
DE4018767A1 (de) * | 1990-06-12 | 1991-12-19 | Braun Melsungen Ag | Wirkstofffreie liposomen zur behandlung von atherosklerose |
US5556637A (en) * | 1990-08-06 | 1996-09-17 | A. Nattermann & Cie. Gmbh | Water containing liposome system |
IT1249063B (it) * | 1991-05-28 | 1995-02-11 | Fidia Spa | Impiego di derivati fosfolipidici per la preparazione di composizioni farmaceutiche aventi attivita' immunosoppressiva |
EP0673384A4 (en) * | 1992-12-10 | 1996-10-09 | Univ Minnesota | POLYPEPTIDES USEFUL IN TREATING INFLAMMABLE DISEASES. |
US5637315A (en) * | 1993-01-04 | 1997-06-10 | Thomas Jefferson University | Treatment of disease states induced by oxidative stress |
ES2072223B1 (es) * | 1993-11-25 | 1996-03-16 | Lipotec Sa | Liposomas encapsulando doxorubicina. |
US5746223A (en) * | 1996-10-11 | 1998-05-05 | Williams; Kevin Jon | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis |
US6312719B1 (en) * | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
US6139871A (en) * | 1995-07-26 | 2000-10-31 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
AU1751795A (en) * | 1994-03-04 | 1995-09-18 | University Of British Columbia, The | Liposome compositions and methods for the treatment of atherosclerosis |
US6773719B2 (en) * | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
JPH08183740A (ja) * | 1994-12-28 | 1996-07-16 | Nippon Steel Corp | 細胞接着阻害剤及び該阻害剤を含む抗炎症剤 |
US5643599A (en) * | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
US5741514A (en) * | 1995-08-31 | 1998-04-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for reducing serum lipoprotein(a) concentration |
WO1997009989A1 (en) * | 1995-09-14 | 1997-03-20 | Lxr Biotechnology Inc. | Compositions with anti-apoptotic activity, containing a mixture of phospholipids |
EP0863748A4 (en) * | 1995-10-11 | 1999-11-03 | Kevin Jon William | LIPOSOMAL COMPOSITIONS AND METHODS OF USE |
US6491922B1 (en) * | 1996-02-09 | 2002-12-10 | Cornell Research Foundation, Inc. | Methods and compounds for treating autoimmune and vascular disease |
EP0914094A4 (en) * | 1996-03-28 | 2000-03-01 | Univ Illinois | MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS |
US20020115609A1 (en) * | 1997-07-14 | 2002-08-22 | Hayat Onyuksel | Materials and methods for making improved micelle compositions |
JPH11308562A (ja) * | 1998-04-20 | 1999-11-05 | Minolta Co Ltd | デジタルカメラシステム |
US6251932B1 (en) * | 1998-09-25 | 2001-06-26 | Asta Medica Ag | Immunophilin ligands |
WO2002009678A2 (en) * | 2000-07-31 | 2002-02-07 | Ottawa Heart Institute Research Corporation | Charged phospholipid compositions and methods for their use |
-
2002
- 2002-01-21 CA CA002368656A patent/CA2368656A1/en not_active Abandoned
-
2003
- 2003-01-17 CA CA002416791A patent/CA2416791A1/en not_active Abandoned
- 2003-01-21 BR BR0307041-7A patent/BR0307041A/pt not_active IP Right Cessation
- 2003-01-21 WO PCT/CA2003/000065 patent/WO2003061667A1/en active Application Filing
- 2003-01-21 MX MXPA04007042A patent/MXPA04007042A/es not_active Application Discontinuation
- 2003-01-21 JP JP2003561610A patent/JP2005515242A/ja active Pending
- 2003-01-21 TW TW092101236A patent/TW200302281A/zh unknown
- 2003-01-21 AR ARP030100172A patent/AR047005A1/es not_active Application Discontinuation
- 2003-01-21 EP EP03700265A patent/EP1467740A1/en not_active Withdrawn
- 2003-01-21 AR ARP030100173A patent/AR038203A1/es not_active Application Discontinuation
- 2003-01-21 CA CA002471740A patent/CA2471740A1/en not_active Abandoned
- 2003-01-21 US US10/348,600 patent/US20030175334A1/en not_active Abandoned
- 2003-01-21 CA CA002473395A patent/CA2473395A1/en not_active Abandoned
- 2003-01-21 KR KR10-2004-7011280A patent/KR20040089118A/ko not_active Application Discontinuation
- 2003-01-21 WO PCT/CA2003/000064 patent/WO2003061666A1/en active Application Filing
- 2003-01-21 BR BR0307018-2A patent/BR0307018A/pt not_active IP Right Cessation
- 2003-01-21 EP EP20030700266 patent/EP1467741A1/en not_active Withdrawn
- 2003-01-21 US US10/348,601 patent/US20040013718A1/en not_active Abandoned
- 2003-01-21 TW TW092101231A patent/TWI283181B/zh not_active IP Right Cessation
- 2003-01-21 EA EA200400888A patent/EA007426B1/ru not_active IP Right Cessation
- 2003-01-21 PE PE2003000064A patent/PE20030973A1/es not_active Application Discontinuation
- 2003-01-21 JP JP2003561611A patent/JP2005515243A/ja active Pending
- 2003-01-21 CN CNA03802537XA patent/CN1620301A/zh active Pending
- 2003-01-21 WO PCT/CA2003/000066 patent/WO2003061620A2/en not_active Application Discontinuation
- 2003-01-21 CA CA002473490A patent/CA2473490A1/en not_active Abandoned
-
2004
- 2004-07-16 MA MA27788A patent/MA27168A1/fr unknown
-
2007
- 2007-11-28 US US11/946,785 patent/US20080160074A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20040089118A (ko) | 2004-10-20 |
CA2471740A1 (en) | 2003-07-31 |
CA2473490A1 (en) | 2003-07-31 |
CA2473395A1 (en) | 2003-07-31 |
BR0307041A (pt) | 2004-10-26 |
US20080160074A1 (en) | 2008-07-03 |
CA2368656A1 (en) | 2003-07-21 |
WO2003061620A3 (en) | 2003-10-16 |
EP1467740A1 (en) | 2004-10-20 |
MA27168A1 (fr) | 2005-01-03 |
JP2005515243A (ja) | 2005-05-26 |
WO2003061666A1 (en) | 2003-07-31 |
CN1620301A (zh) | 2005-05-25 |
TW200302735A (en) | 2003-08-16 |
AR038203A1 (es) | 2005-01-05 |
TW200302281A (en) | 2003-08-01 |
EA200400888A1 (ru) | 2005-04-28 |
BR0307018A (pt) | 2005-02-09 |
CA2416791A1 (en) | 2003-07-21 |
WO2003061620A2 (en) | 2003-07-31 |
AR047005A1 (es) | 2006-01-04 |
MXPA04007042A (es) | 2005-06-20 |
WO2003061667A1 (en) | 2003-07-31 |
US20040013718A1 (en) | 2004-01-22 |
EA007426B1 (ru) | 2006-10-27 |
US20030175334A1 (en) | 2003-09-18 |
JP2005515242A (ja) | 2005-05-26 |
EP1467741A1 (en) | 2004-10-20 |
TWI283181B (en) | 2007-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030973A1 (es) | Cuerpos de inclusion que transportan glicerol-fosfato aceptables para uso farmaceutico | |
AR034746A1 (es) | Combinaciones para el tratamiento de trastornos inflamatorios | |
PH12021550701A1 (en) | Ionizable amine lipids | |
MX2021012934A (es) | Lipidos de amina ionizables y nanoparticulas lipidicas. | |
AR019308A1 (es) | Formulaciones de particulas novedosas. | |
EA202191559A1 (ru) | Модифицированные аминовые липиды | |
AR082579A2 (es) | Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad | |
ES2145118T3 (es) | Derivados de acidos grasos y composiciones farmaceuticas que los contienen. | |
UY34901A (es) | ?monohidrato cristalino, procedimiento para su preparacion ysu utilizacion para la preparacion de un medicamento?. | |
ECSP056132A (es) | Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis | |
AR030068A1 (es) | Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet | |
ES2080844T3 (es) | Composiciones administradas topicamente basadas en acido hialuronico de alto peso molecular para el tratamiento de las inflamaciones de la cavidad oral y para la higiene y el tratamiento cosmetico de la cavidad oral. | |
ECSP12011967A (es) | Métodos y composiciones para el tratamiento rápido de otitis externa | |
ATE287267T1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
CO6280488A2 (es) | Combinacion farmaceutica | |
TR200103271T2 (tr) | İnflamasyon aracılığıyla gerçekleşen infeksiyon için anti-inflamatuar tedavi. | |
PA8613001A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
CO5130021A1 (es) | Reduccion de inactivacion de surfactantes en terapia pulmo nar con surfactantes , | |
ES2054718T3 (es) | El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica. | |
ES2108130T3 (es) | Formulaciones farmacologicas mejoradas. | |
ES2093782T3 (es) | Piridazindionas y su uso en el tratamiento de trastornos neurologicos. | |
ECSP099596A (es) | Composición farmacéutica que contiene una combinación de tramadol y ketoprofeno | |
ATE399558T1 (de) | Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln | |
AR016382A1 (es) | Uso de un derivado del acido bencil-indazol metoxialcanoico. | |
AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |